Tysabri (natalizumab) is effective at reducing the frequency of relapses in patients with relapsing-remitting multiple sclerosis (RRMS) and is rarely associated with poor clinical outcomes, a real-life and multiyear observational study reports.
The study, “Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort,” was published in the Multiple Sclerosis Journal.
Tysabri, marketed by Biogen, is an antibody-based therapy that lessens inflammation in RRMS patients by preventing immune cells from entering the brain. Several clinical trials and real-world studies have found Tysabri to be highly effective at lowering the frequency of relapses, as well as the formation of new MS lesions. These studies supported to its approval for RRMS in both the United States and European Union.
Now, investigators reported the findings of a real-life study looking at the long-term effects of Tysabri’s use by people with RRMS, including the percentage of patients who developed to secondary progressive MS (SPMS) and severe disability while on this treatment.
The study, called TYSTEN (for TYSabri TEN years), enrolled 770 RRMS patients who started treatment with Tysabri between 2007 and 2012, and were followed through October 2018 at two clinical centers in France.
Information regarding the number of MS relapses, the degree of disability — assessed using expanded disability status scale (EDSS) scores — and lesions visible on MRI brain scans were collected every year for each patient. This information was then used to estimate a patient’s chance of having poor clinical outcomes, including developing SPMS or experiencing disability progression (meaning an EDSS worsening).
Patients were followed for an average of 97.2 months (over eight years) and were treated with Tysabri for an average period of 66 months (about 5.5 years).
Treatment with Tysabri was found to be highly effective at reducing MS relapses, lowering their annual frequency by 80.5% at two years of treatment, and by 97.5% at 10 years.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?